Comparative Effectiveness of Troriluzole Versus Untreated Natural History Cohorts in Spinocerebellar Ataxia Leveraging Propensity Score Matching Methods (P6-5.012)
Examine the treatment benefits of troriluzole over 3 years in patients with Spinocerebellar Ataxia (SCA) by conducting a matched comparison of troriluzole-treated subjects vs untreated external controls.
Authors
- Irfan Qureshi (ORCID: https://orcid.org/0000-0002-0572-0993)
- Melissa Beiner
- Jeremy D. Schmahmann (ORCID: https://orcid.org/0000-0003-0706-5125)
- Liana S. Rosenthal (ORCID: https://orcid.org/0000-0001-5140-3967)
- Vlad Coric
- Sheng‐Han Kuo (ORCID: https://orcid.org/0000-0002-9412-931X)
- Lauren Powell (ORCID: https://orcid.org/0000-0002-4329-5166)
- Basia Rogula (ORCID: https://orcid.org/0000-0002-2115-8275)
- Michele Potashman (ORCID: https://orcid.org/0000-0001-7389-3354)
- David Stock
- Victoria Wirtz
- Susan B. Perlman
- Gilbert L’Italien
Institutions
- Biohaven Pharmaceuticals (United States) (US)
- Columbia University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000209018
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00